Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults. More: Lilly files lasmiditan for migraine Source: News
read morePfizer launched its third biosim, Retacrit, at a significant discount to anemia drugs from Amgen and Johnson & Johnson. More: Pfizer rolls out Retacrit, a biosim to Amgen and J&J anemia blockbusters, at a big discount Source: fierce
read moreEntry has now closed for the inaugural PharmaTimes Medical & Scientific Awards, join us at the gala dinner awards ceremony where our winners will be revealed. More: Entry closes as countdown to the competition & awards ceremony begins Source: News
read moreSouth Korean stock regulators have ruled that Samsung BioLogics intentionally violated accounting rules to inflate its value tied to its Biogen-partnered affiliate Samsung Bioepis before going public in 2016. More: Samsung BioLogics stock listing, CEO in jeopardy over accounting fraud
read morePfizer has come up short in a long-running patent battle in the U.K. over its blockbuster Lyrica, and the loss could come with a significant financial hit for the drugmaker. More: Pfizer falls short in U.K. patent appeal for blockbuster
read moreNovartis filed a registration statement with the SEC for the spinoff of its eye-care unit, Alcon. It hasn’t placed a valuation on the transaction just yet, but previous CEO Joe Jimenez said last year it could be worth as much
read more© 1994 - 2026 B.M. Pharmaceuticals